
There is clear evidence that primary antibody deficiency (PAD) prevalence is higher in patients with recurrent and chronic rhinosinusitis (CRS) than in the general population. The purpose of the study is to review the literature on rhinosinusitis with PAD thoroughly, summarize the existing evidence, and provide recommendations on the evaluation and management of rhinosinusitis in patients with PAD. A total of 42 studies were included in this evidence‐based review. Based on current evidence, PAD can occur in up to 50% of patients with recalcitrant CRS. Despite the presence of multiple studies addressing rhinosinusitis and PAD, the level of evidence supporting different treatment options continues to be lacking. Optimal management requires a multidisciplinary approach through collaboration with clinical immunology.
Like
Save
Share